{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:53:59Z","timestamp":1782842039342,"version":"3.54.5"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Advanced Discipline Deployment Fund of Sichuan University","doi-asserted-by":"publisher","award":["0040204151020"],"award-info":[{"award-number":["0040204151020"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiretroviral therapy (ART) has significantly increased the life expectancy of people living with human immunodeficiency virus (PLWH), resulting in a growing need for the treatment of Helicobacter pylori infections in this population. H. pylori treament among PLWH who are on ART can be challenging due to potential drug-drug interactions (H. pylori eradication drugs interact with ART drugs). This study aimed to evaluate the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy for H. pylori infection among PLWH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 201 treatment-naive, H. pylori\u00ad\u2013positive PLWH on ART were enrolled to receive vonoprazan (20\u2005mg twice daily) plus amoxicillin (1000\u2005mg 3 times daily) for 14 days. H. pylori eradication status was assessed using the urease breath test \u22654 weeks after treatment. Patient compliance and adverse events (AEs) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 201 participants, 181 (90.0%) completed the treatment course. Nineteen patients were lost to follow-up, and 1 discontinued treatment due to a rash. The eradication rates were 74.6% (150 of 201) by intention-to-treat analysis, 82.9% (150 of 181) by modified intention-to-treat analysis, and 90.6% (145 of 160) by per-protocol analysis. AEs occurred in 10 patients (5.0%), including abdominal distension in 5 and abdominal pain, nausea, diarrhea, fatigue, and rash, each occurring in 1 patient. Most AEs were mild and resolved spontaneously after treatment. Good compliance (odds ratio, 1.03 [95% confidence interval, 1.01\u20131.11]; P &amp;lt; .001) was independently associated with the efficacy of VA for H. pylori eradication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VA dual therapy as a first-line treatment for H. pylori infection among PLWH on ART demonstrates good efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>ChiCTR2400085762<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf386","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:42:45Z","timestamp":1753357365000},"page":"S367-S374","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for\n                    <i>Helicobacter pylori<\/i>\n                    Infection Among People Living With HIV"],"prefix":"10.1093","volume":"232","author":[{"given":"Jinzhi","family":"Zhang","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Infection, West China Tianfu Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Song","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Shen","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghua","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Zhaojue County People's Hospital , Xichang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred C Y","family":"Tay","sequence":"additional","affiliation":[{"name":"Helicobacter pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Diseases Research and Training, University of Western Australia , Nedlands ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J","family":"Marshall","sequence":"additional","affiliation":[{"name":"Helicobacter pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Diseases Research and Training, University of Western Australia , Nedlands ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3528-0448","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025112010500932800_jiaf386-B1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"2025112010500932800_jiaf386-B2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025112010500932800_jiaf386-B3","author":"UNAIDS","year":"28  2025"},{"key":"2025112010500932800_jiaf386-B4","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"2025112010500932800_jiaf386-B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijregi.2022.01.007","article-title":"Prevalence of H. pylori among asymptomatic HIV-positive and negative individuals in central Ethiopia and efficacy of eradication therapy","volume":"2","author":"Mesfun","year":"2022","journal-title":"IJID Reg"},{"key":"2025112010500932800_jiaf386-B6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s40001-024-01750-6","article-title":"CD4+ T cell count and HIV-1 viral load dynamics positively impacted by H. pylori infection in HIV-positive patients regardless of ART status in a high-burden setting","volume":"29","author":"Abadi","year":"2024","journal-title":"Eur J Med Res"},{"key":"2025112010500932800_jiaf386-B7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jiac.2022.04.015","article-title":"Seroprevalence of Helicobacter pylori in human immunodeficiency virus-infected patients in a tertiary care hospital in Busan, South Korea","volume":"28","author":"Lee","year":"2022","journal-title":"J Infect Chemother"},{"key":"2025112010500932800_jiaf386-B8","first-page":"1761","article-title":"Helicobacter pylori-associated gastritis is rare in AIDS: antibiotic effect or a consequence of immunodeficiency?","volume":"86","author":"Edwards","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"2025112010500932800_jiaf386-B9","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","article-title":"AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review","volume":"160","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"2025112010500932800_jiaf386-B10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","article-title":"Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis","volume":"150","author":"Lee","year":"2016","journal-title":"Gastroenterology"},{"key":"2025112010500932800_jiaf386-B11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3390\/microorganisms10081541","article-title":"Issues related to the treatment of H. pylori infection in people living with HIV and receiving antiretrovirals","volume":"10","author":"Nkuize","year":"2022","journal-title":"Microorganisms"},{"key":"2025112010500932800_jiaf386-B12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/hiv.13083","article-title":"Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients","volume":"22","author":"Nkuize","year":"2021","journal-title":"HIV Med"},{"key":"2025112010500932800_jiaf386-B13","doi-asserted-by":"crossref","first-page":"e0145119","DOI":"10.1371\/journal.pone.0145119","article-title":"HIV-Helicobacter pylori co-infection: antibiotic resistance, prevalence, and risk factors","volume":"10","author":"Nkuize","year":"2015","journal-title":"PLoS One"},{"key":"2025112010500932800_jiaf386-B14","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2025112010500932800_jiaf386-B15","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"2025112010500932800_jiaf386-B16","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"2025112010500932800_jiaf386-B17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: a review in Helicobacter pylori infection","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"2025112010500932800_jiaf386-B18","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/j.ijid.2009.03.036","article-title":"Eradication of Helicobacter pylori can facilitate immune reconstitution in HIV-1-infected immunological non-responders","volume":"14","author":"Magen","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2025112010500932800_jiaf386-B19","doi-asserted-by":"crossref","first-page":"e1184","DOI":"10.1002\/mbo3.1184","article-title":"Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: a descriptive observational study","volume":"10","author":"Nkuize","year":"2021","journal-title":"Microbiologyopen"},{"key":"2025112010500932800_jiaf386-B20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3390\/antibiotics12121669","article-title":"Antibiotic resistance and therapy for Helicobacter pylori infection","volume":"12","author":"Smith","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2025112010500932800_jiaf386-B21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025112010500932800_jiaf386-B22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.cgh.2017.09.033","article-title":"Interchangeable use of proton pump inhibitors based on relative potency","volume":"16","author":"Graham","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025112010500932800_jiaf386-B23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ueg2.12476","article-title":"Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management","volume":"12","author":"Pab\u00f3n-Carrasco","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2025112010500932800_jiaf386-B24","first-page":"e673","article-title":"The best strategy for Helicobacter pylori eradication in people living with HIV in the era of antibiotic resistance","volume":"4","author":"Nkuize","year":"2022","journal-title":"Microb Health Dis"},{"key":"2025112010500932800_jiaf386-B25","author":"Liverpool TUO","year":"26  2025"},{"key":"2025112010500932800_jiaf386-B26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/0091270007309706","article-title":"Darunavir\/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers","volume":"48","author":"Sekar","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"2025112010500932800_jiaf386-B27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-151-4-200908180-00006","article-title":"Five-year outcomes of the China national free antiretroviral treatment program","volume":"151","author":"Zhang","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025112010500932800_jiaf386-B28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s13181-015-0465-0","article-title":"A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products","volume":"11","author":"Stolbach","year":"2015","journal-title":"J Med Toxicol"},{"key":"2025112010500932800_jiaf386-B29","doi-asserted-by":"crossref","first-page":"e13094","DOI":"10.1111\/hel.13094","article-title":"Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: systematic review and meta-analyses of randomized controlled trials","volume":"29","author":"Liu","year":"2024","journal-title":"Helicobacter"},{"key":"2025112010500932800_jiaf386-B30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive acid blockers: current clinical use and future developments","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"key":"2025112010500932800_jiaf386-B31","doi-asserted-by":"crossref","first-page":"e13040","DOI":"10.1111\/hel.13040","article-title":"Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2024","journal-title":"Helicobacter"},{"key":"2025112010500932800_jiaf386-B32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy","volume":"118","author":"Qian","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025112010500932800_jiaf386-B33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00535-023-02042-2","article-title":"Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study","volume":"58","author":"Han","year":"2023","journal-title":"J Gastroenterol"},{"key":"2025112010500932800_jiaf386-B34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.gastro.2022.03.039","article-title":"Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up","volume":"163","author":"Yan","year":"2022","journal-title":"Gastroenterology"},{"key":"2025112010500932800_jiaf386-B35","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jgh.15917","article-title":"Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"37","author":"Ouyang","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2025112010500932800_jiaf386-B36","doi-asserted-by":"crossref","first-page":"1049908","DOI":"10.3389\/fimmu.2022.1049908","article-title":"Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"2025112010500932800_jiaf386-B37","doi-asserted-by":"crossref","first-page":"17562848241299734","DOI":"10.1177\/17562848241299734","article-title":"The efficacy and safety of a simple 14-day vonoprazan-minocycline dual therapy for Helicobacter pylori eradication: a retrospective pilot study","volume":"17","author":"Wang","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"2025112010500932800_jiaf386-B38","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/gutjnl-2024-332640","article-title":"Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy","volume":"73","author":"Gao","year":"2024","journal-title":"Gut"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_4\/S367\/65408926\/jiaf386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_4\/S367\/65408926\/jiaf386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:50:20Z","timestamp":1763653820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/Supplement_4\/S367\/8329321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":38,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2025,11,20]]},"published-print":{"date-parts":[[2025,11,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf386","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,11,15]]}}}